Membranous nephropathy

Fernando Custodio Fervenza, Patrizia Passerini, Sanjeev M Sethi, Claudio Ponticelli

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Primary membranous nephropathy is the most common form of nephrotic syndrome in Caucasian adults and a frequent cause of end-stage renal disease. It is characterized by sub-epithelial immune deposits and is the prototype of an autoimmune glomerular disease. Clinical course is variable and up to 30 % of patients may go into spontaneous remission. The discovery of two major podocytes antigens: neutral endopeptidase (NEP), involved in rare cases of neonatal MN, and the M-type phospholipase-A<inf>2</inf> receptor 1 (PLA<inf>2</inf>R1) the first antigen discovered in adults, have been major breakthroughs in our understanding of the pathogenesis of human MN. The presence of circulating antibodies against bovine serum album in some children with membranous nephropathy raises the possibility that food antigens may also be involved in its pathogenesis. Genetic susceptibility studies have linked single-nucleotide polymorphisms (SNPs) in the genes encoding M-type phospholipase A<inf>2</inf> receptor 1 (PLA<inf>2</inf>R) and HLA complex class II HLA-DQ alpha chain 1 (HLA-DQA1) in Caucasian populations with membranous nephropathy. Current therapies include combined use of corticosteroids and alkylating agents, or calcineurin inhibitors. The first treatment may favor remission and protect renal function but may be associated with significant adverse effects. Calcineurin inhibitors may reduce proteinuria but have a high relapse rate. New therapies have being sought with the use of adrenocorticotropic hormone and rituximab. Further research may facilitate a more patient-specific treatment approach in these patients.

Original languageEnglish (US)
Title of host publicationCore Concepts in Parenchymal Kidney Disease
PublisherSpringer New York
Pages51-75
Number of pages25
ISBN (Print)9781461481669, 1461481651, 9781461481652
DOIs
StatePublished - Jul 1 2013

Fingerprint

Membranous Glomerulonephritis
Phospholipase A2 Receptors
HLA-DQ alpha-Chains
Antigens
Spontaneous Remission
Neprilysin
Podocytes
Alkylating Agents
Nephrotic Syndrome
Therapeutics
Genetic Predisposition to Disease
Proteinuria
Adrenocorticotropic Hormone
Autoimmune Diseases
Chronic Kidney Failure
Single Nucleotide Polymorphism
Adrenal Cortex Hormones
Kidney
Recurrence
Food

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fervenza, F. C., Passerini, P., Sethi, S. M., & Ponticelli, C. (2013). Membranous nephropathy. In Core Concepts in Parenchymal Kidney Disease (pp. 51-75). Springer New York. https://doi.org/10.1007/978-1-4614-8166-9_5

Membranous nephropathy. / Fervenza, Fernando Custodio; Passerini, Patrizia; Sethi, Sanjeev M; Ponticelli, Claudio.

Core Concepts in Parenchymal Kidney Disease. Springer New York, 2013. p. 51-75.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fervenza, FC, Passerini, P, Sethi, SM & Ponticelli, C 2013, Membranous nephropathy. in Core Concepts in Parenchymal Kidney Disease. Springer New York, pp. 51-75. https://doi.org/10.1007/978-1-4614-8166-9_5
Fervenza FC, Passerini P, Sethi SM, Ponticelli C. Membranous nephropathy. In Core Concepts in Parenchymal Kidney Disease. Springer New York. 2013. p. 51-75 https://doi.org/10.1007/978-1-4614-8166-9_5
Fervenza, Fernando Custodio ; Passerini, Patrizia ; Sethi, Sanjeev M ; Ponticelli, Claudio. / Membranous nephropathy. Core Concepts in Parenchymal Kidney Disease. Springer New York, 2013. pp. 51-75
@inbook{7ff8da3937e446a9aa40b3d9cc9cf471,
title = "Membranous nephropathy",
abstract = "Primary membranous nephropathy is the most common form of nephrotic syndrome in Caucasian adults and a frequent cause of end-stage renal disease. It is characterized by sub-epithelial immune deposits and is the prototype of an autoimmune glomerular disease. Clinical course is variable and up to 30 {\%} of patients may go into spontaneous remission. The discovery of two major podocytes antigens: neutral endopeptidase (NEP), involved in rare cases of neonatal MN, and the M-type phospholipase-A2 receptor 1 (PLA2R1) the first antigen discovered in adults, have been major breakthroughs in our understanding of the pathogenesis of human MN. The presence of circulating antibodies against bovine serum album in some children with membranous nephropathy raises the possibility that food antigens may also be involved in its pathogenesis. Genetic susceptibility studies have linked single-nucleotide polymorphisms (SNPs) in the genes encoding M-type phospholipase A2 receptor 1 (PLA2R) and HLA complex class II HLA-DQ alpha chain 1 (HLA-DQA1) in Caucasian populations with membranous nephropathy. Current therapies include combined use of corticosteroids and alkylating agents, or calcineurin inhibitors. The first treatment may favor remission and protect renal function but may be associated with significant adverse effects. Calcineurin inhibitors may reduce proteinuria but have a high relapse rate. New therapies have being sought with the use of adrenocorticotropic hormone and rituximab. Further research may facilitate a more patient-specific treatment approach in these patients.",
author = "Fervenza, {Fernando Custodio} and Patrizia Passerini and Sethi, {Sanjeev M} and Claudio Ponticelli",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-1-4614-8166-9_5",
language = "English (US)",
isbn = "9781461481669",
pages = "51--75",
booktitle = "Core Concepts in Parenchymal Kidney Disease",
publisher = "Springer New York",

}

TY - CHAP

T1 - Membranous nephropathy

AU - Fervenza, Fernando Custodio

AU - Passerini, Patrizia

AU - Sethi, Sanjeev M

AU - Ponticelli, Claudio

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Primary membranous nephropathy is the most common form of nephrotic syndrome in Caucasian adults and a frequent cause of end-stage renal disease. It is characterized by sub-epithelial immune deposits and is the prototype of an autoimmune glomerular disease. Clinical course is variable and up to 30 % of patients may go into spontaneous remission. The discovery of two major podocytes antigens: neutral endopeptidase (NEP), involved in rare cases of neonatal MN, and the M-type phospholipase-A2 receptor 1 (PLA2R1) the first antigen discovered in adults, have been major breakthroughs in our understanding of the pathogenesis of human MN. The presence of circulating antibodies against bovine serum album in some children with membranous nephropathy raises the possibility that food antigens may also be involved in its pathogenesis. Genetic susceptibility studies have linked single-nucleotide polymorphisms (SNPs) in the genes encoding M-type phospholipase A2 receptor 1 (PLA2R) and HLA complex class II HLA-DQ alpha chain 1 (HLA-DQA1) in Caucasian populations with membranous nephropathy. Current therapies include combined use of corticosteroids and alkylating agents, or calcineurin inhibitors. The first treatment may favor remission and protect renal function but may be associated with significant adverse effects. Calcineurin inhibitors may reduce proteinuria but have a high relapse rate. New therapies have being sought with the use of adrenocorticotropic hormone and rituximab. Further research may facilitate a more patient-specific treatment approach in these patients.

AB - Primary membranous nephropathy is the most common form of nephrotic syndrome in Caucasian adults and a frequent cause of end-stage renal disease. It is characterized by sub-epithelial immune deposits and is the prototype of an autoimmune glomerular disease. Clinical course is variable and up to 30 % of patients may go into spontaneous remission. The discovery of two major podocytes antigens: neutral endopeptidase (NEP), involved in rare cases of neonatal MN, and the M-type phospholipase-A2 receptor 1 (PLA2R1) the first antigen discovered in adults, have been major breakthroughs in our understanding of the pathogenesis of human MN. The presence of circulating antibodies against bovine serum album in some children with membranous nephropathy raises the possibility that food antigens may also be involved in its pathogenesis. Genetic susceptibility studies have linked single-nucleotide polymorphisms (SNPs) in the genes encoding M-type phospholipase A2 receptor 1 (PLA2R) and HLA complex class II HLA-DQ alpha chain 1 (HLA-DQA1) in Caucasian populations with membranous nephropathy. Current therapies include combined use of corticosteroids and alkylating agents, or calcineurin inhibitors. The first treatment may favor remission and protect renal function but may be associated with significant adverse effects. Calcineurin inhibitors may reduce proteinuria but have a high relapse rate. New therapies have being sought with the use of adrenocorticotropic hormone and rituximab. Further research may facilitate a more patient-specific treatment approach in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84929565226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929565226&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8166-9_5

DO - 10.1007/978-1-4614-8166-9_5

M3 - Chapter

AN - SCOPUS:84949180334

SN - 9781461481669

SN - 1461481651

SN - 9781461481652

SP - 51

EP - 75

BT - Core Concepts in Parenchymal Kidney Disease

PB - Springer New York

ER -